☆ 4.7 Editorial Material

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

ONCOLOGIST (2017)

期刊

ONCOLOGIST

卷 22, 期 6, 页码 627-630

出版社

WILEY

DOI: 10.1634/theoncologist.2016-0390

关键词

-

类别

Oncology

资金

National Institute of Arthritis and Musculoskeletal and Skin Diseases [P30-AR053503]
NIH [DE-12354-15A1]
Jerome L. Greene Foundation Scholar Award
Jerome L. Greene Foundation Discovery Award

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update

Quang Minh Dang, Ryu Watanabe, Mayu Shiomi, Kazuo Fukumoto, Tomomi W. Nobashi, Tadashi Okano, Shinsuke Yamada, Motomu Hashimoto

Summary: With the increase in elderly patients, malignancies are becoming more common in rheumatoid arthritis (RA) patients and often pose challenges to RA treatment. Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for various malignancies by blocking immunological brakes on T lymphocytes. However, ICIs are also associated with numerous immune-related adverse events (irAEs) including hypophysitis, myocarditis, pneumonitis, and colitis. Moreover, ICIs can exacerbate existing autoimmune diseases and cause rheumatic irAEs such as arthritis, myositis, and vasculitis. This review provides a comprehensive summary of the mechanisms, management, and potential therapeutic strategies for rheumatic irAEs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Review Rheumatology

Rheumatologic immune checkpoint inhibitor-related adverse events

Melissa Defoe, Bonnie L. Bermas

Summary: This review article discusses immune check point inhibitors (ICIs) as a unique class of cancer treatments that activate the body's innate antitumor response. However, these medications can also cause generalized immune activation and result in immune-related adverse events across various organ systems. The article focuses on the most common rheumatologic immune-related adverse events and their management.

CURRENT OPINION IN RHEUMATOLOGY (2023)

添加到收藏夹

Review Oncology

Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis

Yiqun Han, Jiayu Wang, Binghe Xu

Summary: The study found that cutaneous irAEs are dose-independent and agent-specific immune reactions, with the highest risk observed in CTLA-4 blockade, and may not serve as a surrogate prognostic indicator.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Review Biology

Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy

Anca Bobirca, Florin Bobirca, Ioan Ancuta, Alesandra Florescu, Vlad Padureanu, Dan Nicolae Florescu, Rodica Padureanu, Anca Florescu, Anca Emanuela Musetescu

Summary: Cancer therapy has evolved over the years, with immunotherapy being widely used for untreatable malignant tumors. Although immune checkpoint inhibitors have a significant impact on cancer treatment, they are associated with various adverse effects, mostly inflammation. These adverse events can affect various tissues in the human body, requiring a multidisciplinary approach for management.

BIOLOGY-BASEL (2021)

添加到收藏夹

Article Oncology

Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea

Jae-Won Hyun, Ki Hoon Kim, Su-Hyun Kim, Ho Jin Kim

Summary: This study evaluated the occurrence and management of neuromuscular irAEs induced by ICIs at the National Cancer Center in Korea, and found that while rare, these irAEs can have devastating outcomes.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis

Xiao-Tong Zhang, Nan Ge, Zi-Jian Xiang, Tao Liu

Summary: This study evaluated the incidence of cardiotoxicity related to immune checkpoint inhibitor (ICI) therapies for lung cancer. The results showed that single ICI did not increase the risk of cardiotoxicity compared to chemotherapy, while single ICI plus chemotherapy increased the risk of cardiotoxicity by 67% compared to chemotherapy alone. Combination immunotherapy did not increase the risk of cardiotoxicity compared to single ICI.

CANCER CELL INTERNATIONAL (2022)

添加到收藏夹

Article Oncology

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy

Bettzy Stephen, Joud Hajjar, Shrutii Sarda, Dzifa Yawa Duose, Jeffrey M. Conroy, Carl Morrison, Anas Alshawa, Mingxuan Xu, Abdulrazzak Zarifa, Sapna P. Patel, Ying Yuan, Evan Kwiatkowski, Linghua Wang, Jordi Rodon Ahnert, Siqing Fu, Funda Meric-Bernstam, Geoffrey M. Lowman, Timothy Looney, Aung Naing

Summary: Immune checkpoint inhibitors have greatly improved cancer treatment but also come with immune-related adverse events (irAEs). Evaluating the link between polymorphisms in the TRBV gene and irAEs could help find predictive biomarkers. Long-amplicon TCRB sequencing may identify TRBV haplotypes associated with the risk of severe irAEs.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Immunology

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

Li Zeng, Gang Ma, Kai Chen, Qiao Zhou

Summary: This study examined the trend of ICIs-associated rheumatic irAEs using bibliometric methods, finding that the United States is the leading contributor and observing shifts in research focus through keyword analysis and citation bursts.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Oncology

Association between immune-related adverse event timing and treatment outcomes

David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S. Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H. Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E. Gerber

Summary: The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) varies greatly. Late-onset irAE is associated with better clinical outcomes compared to early-onset irAE.

ONCOIMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor

Xin Bai, Xueyan Wang, Guozhen Ma, Jinen Song, Xiaowei Liu, Xi Wu, Yujie Zhao, Xu Liu, Zhihui Liu, Wei Zhang, Xin Zhao, Zirui Zheng, Jing Jing, Hubing Shi

Summary: Immunotherapy, particularly the ICB treatment, has shown durable tumor inhibition but can lead to severe immune-related adverse events. Research found that ICB treatment induces colitis in melanoma patients and activates the PI3K-AKT-mTOR pathway in affected T cells. In a mouse model, combining mTOR inhibitor sirolimus with anti-PD-1 treatment effectively inhibits tumor growth by inducing immunogenic cell death.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system

Chen Chen, Bin Wu, ChenYu Zhang, Ting Xu

Summary: This study analyzed immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) and found different characteristics of irAEs among different ICI regimens. Pembrolizumab had the highest fatality proportion, while ipilimumab plus pembrolizumab had the shortest median time to onset irAEs. Further studies are needed to assess potential clinically relevant differences among ICIs.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Review Oncology

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review

Josefien W. Hommes, Rik J. Verheijden, Karijn P. M. Suijkerbuijk, Dorte Hamann

Summary: ICIs have improved cancer patient prognosis by blocking negative feedback mechanisms of the immune system, but can also lead to auto-immune toxicities. Despite numerous studies, no single biomarker has yet been proven to sufficiently predict the development of irAEs.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events

Zachary Garrison, Matthew Chang, Noah Hornick, Wesley Y. Yu, Jeffrey B. Cheng, Rajan P. Kulkarni

Summary: Immunotherapy has become a popular option in cancer care, but it comes with the risk of immune related adverse events (irAEs). To understand the mechanisms behind these side effects, researchers analyzed single cell sequencing data and identified macrophage population trends and upregulated reactive oxygen species related pathways.

CANCERS (2022)

添加到收藏夹

Article Medicine, General & Internal

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma - a phase 3 randomised trial

Peey Sei Kok, Patrick M. Forde, Brett Hughes, Zhuoxin Sun, Chris Brown, Suresh Ramalingam, Alistair Cook, Willem Joost Lesterhuis, Sonia Yip, Ken O'Byrne, Nick Pavlakis, Julie Brahmer, Valsamo Anagnostou, Kate Ford, Karen Fitzpatrick, Alison Bricker, Michelle M. Cummins, Martin Stockler, Anna K. Nowak

Summary: The DREAM3R trial aims to assess the efficacy of combining PD-L1 inhibitor durvalumab with first-line chemotherapy in pleural mesothelioma. This multicentre, open-label randomized trial will recruit 480 treatment-naive patients and evaluate various endpoints, including overall survival and adverse events.

BMJ OPEN (2022)

添加到收藏夹

Article Rheumatology

Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population

Christopher A. Mecoli, Tak Igusa, Mengkun Chen, XingYao Wang, Jemima Albayda, Julie J. Paik, Eleni Tiniakou, Brittany Adler, Carrie Richardson, Will Kelly, Sonye Danoff, Andrew L. Mammen, Elizabeth A. Platz, Antony Rosen, Lisa Christopher-Stine, Livia Casciola-Rosen, Ami A. Shah

Summary: This study investigated the cancer risk in patients with idiopathic inflammatory myopathy (IIM) compared to the general population. The results showed that IIM patients had a 1.43-fold increased risk of developing cancer. Specific autoantibodies, such as anti-transcription intermediary factor 1 gamma (anti-TIF1 gamma), were associated with an increased risk of ovarian and breast cancer.

ARTHRITIS & RHEUMATOLOGY (2023)

添加到收藏夹

Article Oncology

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

Susan C. Scott, Xiaoshan M. Shao, Noushin Niknafs, Archana Balan, Gavin Pereira, Kristen A. Marrone, Vincent K. Lam, Joseph C. Murray, Josephine L. Feliciano, Benjamin P. Levy, David S. Ettinger, Christine L. Hann, Julie R. Brahmer, Patrick M. Forde, Rachel Karchin, Jarushka Naidoo, Valsamo Anagnostou

Summary: The response to immune checkpoint inhibitor (ICI) therapy may differ based on sex, with lower response rates and decreased survival observed in females. This study investigated the differences in immunogenomic landscape of tumors between males and females and their association with ICI response. The results showed that HLA class II diversity and loss of heterozygosity were associated with higher immunogenic mutation load in female tumors. Higher tumor mutational burden, class I and II immunogenic mutation load, and mutational smoking signature were significantly associated with ICI response in female tumors, while there was no significant association in male tumors. Additionally, high MHC-II restricted immunogenic mutation load and HLA class II diversity were associated with overall survival in males.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Rheumatology

Assessment of the Systemic Sclerosis-Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short-Form Development

Lan Yu, Robyn T. Domsic, Lesley-Ann Saketkoo, Jane Withey, Tracy M. Frech, Ariane L. Herrick, Laura K. Hummers, Ami A. Shah, Christopher P. Denton, Dinesh Khanna, John D. Pauling

Summary: A novel patient-reported outcome instrument, the ASRAP questionnaire, has been developed and scored to assess the severity and impact of RP in SSc. The questionnaire was developed with extensive patient input and went through qualitative assessment and linguistic testing. A long-form and short-form version of the ASRAP questionnaire have been calibrated and scored for formal validation.

ARTHRITIS CARE & RESEARCH (2023)

添加到收藏夹

Article Rheumatology

Outcomes of Filipinos with inflammatory rheumatic diseases developing COVID-19 prior to vaccinations and new variants: a historical perspective

Geraldine Tong Zamora-Abrahan, Evelyn Osio Salido, Juan Javier Tayengco Lichauco, Anna Kristina Manahan Gutierrez-Rubio, Ivy Catherine Talavera Rivera-Go, Karen Joy Castaneda Cortez, Katrina Elys Arada Suilan, Jimmy Gene Bobot Villo, Adora Gatlabayan Del Rosario

Summary: We studied the characteristics and outcomes of Filipino patients with inflammatory rheumatic diseases (IRDs) who developed COVID-19 (IRD-C19) during the early stage of the pandemic, before vaccinations and variants emerged. Data from Filipino patients with IRD-C19 were collected from the Global Rheumatology Alliance registry from March 2020 to August 2021. A total of 164 patients were included, with a mean age of 44 years and 70% being female. The most common IRDs were systemic lupus erythematosus (SLE, 41.4%), rheumatoid arthritis (RA, 15.2%), and gout (14.6%). Majority of the patients were receiving conventional DMARDs (59.1%) and/or glucocorticoid therapy (GC, 51.2%). Half of the patients (58.5%) required hospitalization, with higher risk observed in those with active IRD, heart disease, and hypertension. Among hospitalized patients, 76% needed supplemental oxygen. Higher odds of requiring oxygen supplementation were associated with heart disease, hypertension, and moderate-to-high IRD activity. Hypertension was also associated with mechanical ventilation. A total of 24 patients (15%) died, with lower odds of death observed among those on prednisone >=10 mg/day and patients with autoimmune IRDs other than SLE and RA. This study provides important historical information, highlighting the need for continued data collection to further understand the impact of COVID-19.

CLINICAL RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Associations Between Patterns of Esophageal Dysmotility and Extra-Intestinal Features in Patients With Systemic Sclerosis

Ana E. E. Tucker, Jamie Perin, Elizabeth R. R. Volkmann, Tsion Abdi, Ami A. A. Shah, John Pandolfino, Richard M. M. Silver, Zsuzsanna H. H. McMahan

Summary: This study aimed to investigate whether patterns of esophageal dysfunction in patients with systemic sclerosis (SSc) are associated with specific clinical phenotypes. The results showed that absent contractility (AC) is closely associated with the clinical manifestations of SSc, while ineffective esophageal motility (IEM) may be associated with a milder phenotype.

ARTHRITIS CARE & RESEARCH (2023)

添加到收藏夹

Article Rheumatology

Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

Anne R. Bass, Noha Abdel-Wahab, Pankti D. Reid, Jeffrey A. Sparks, Cassandra Calabrese, Deanna P. Jannat-Khah, Nilasha Ghosh, Divya Rajesh, Carlos Andres Aude, Lydia Gedmintas, Lindsey MacFarlane, Senada Arabelovic, Adewunmi Falohun, Komal Mushtaq, Farah Al Haj, Adi Diab, Ami A. Shah, Clifton O. Bingham, Karmela Kim Chan, Laura C. Cappelli

Summary: This study compares the safety and effectiveness of biologic and conventional DMARDs for ICI-IA. The results show that biologic DMARDs can achieve faster arthritis control than MTX, but may be associated with a shorter time to cancer progression.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Advancing neoadjuvant immunotherapy for lung cancer

Michael Conroy, Patrick M. Forde

Summary: The NEOSTAR trial is an important step towards improving outcomes, but a personalized approach taking into account various factors influencing treatment response is likely the best approach.

NATURE MEDICINE (2023)

添加到收藏夹

Article Rheumatology

Preventative Care in Scleroderma What Is the Best Approach to Bone Health and Cancer Screening?

Leonardo Martin Calderon, Robyn T. Domsic, Ami A. Shah, Janet E. Pope

Summary: A preventative care approach is crucial to reduce the impact of SSc-related complications, such as OP and malignancies. Clinicians should ensure vitamin D levels are normal in SSc patients, as some may still be deficient despite supplementation. Nutritional screening should be conducted, with appropriate interventions for at-risk patients. OP guidelines should be followed for bone density testing and treatment for moderate to high-risk patients. Regular screening for malignancies based on individual risk factors is also recommended.

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2023)

添加到收藏夹

Article Rheumatology

Preventative Care in Scleroderma What Is the Best Approach to Vaccination?

Leonardo Martin Calderon, Janet E. Pope, Ami A. Shah, Robyn T. Domsic

Summary: There are complications associated with SSc that can be prevented or reduced through proper screening and treatment, such as preventing infections with routine vaccinations. Patients with SSc may experience decreased seroconversion due to immunosuppressants, and temporary DMARD suspension may be necessary for vaccinations. Additionally, a prime-boost approach to influenza vaccination may benefit patients.

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2023)

添加到收藏夹

Article Rheumatology

Diagnostic Yield of Computed Tomography for Cancer Detection in a Tertiary Referral Population of Idiopathic Inflammatory Myositis Patients

Christopher A. Mecoli, Brant Chee, Mengkun Chen, XingYao Wang, Jemima Albayda, Julie J. Paik, Eleni Tiniakou, Brittany Adler, Will Kelly, Andrew L. Mammen, Elizabeth A. Platz, Livia Casciola-Rosen, Lisa Christopher-Stine, Ami A. Shah

Summary: This study evaluated the diagnostic yield of computed tomography (CT) imaging for cancer screening/surveillance in patients with idiopathic inflammatory myopathy (IIM). The results showed that dermatomyositis patients had the highest diagnostic yields on CT scans of the chest and abdomen/pelvis, while patients under 40 years old had lower diagnostic yields.

ARTHRITIS CARE & RESEARCH (2023)

添加到收藏夹

Article Rheumatology

Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis

David Fiorentino, Christopher A. Mecoli, Tak Igusa, Jemima Albayda, Julie J. Paik, Eleni Tiniakou, Brittany Adler, Andrew L. Mammen, Ami A. Shah, Antony Rosen, Lisa Christopher-Stine, Livia Casciola-Rosen

Summary: This study demonstrates the disease specificity and clinical significance of anti-CCAR1 autoantibodies in dermatomyositis (DM) patients. It also reveals a lower risk of cancer in DM patients with anti-TIF1 gamma positive and anti-CCAR1 positive status.

ARTHRITIS & RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis

Robyn T. Domsic, Robin Pokrzywinski, Larissa Stassek, Wade W. Benton, Christa-Lynn Vampola, Daniel E. Furst, Lorinda Chung, Virginia Steen, Maureen D. Mayes, Ami A. Shah, Jerry A. Molitor, Kelly Oliver, Vivek Nagaraja, Dinesh Khanna

Summary: The study aimed to understand the symptoms and impacts of Raynaud phenomenon (RP) in patients with systemic sclerosis (SSc) and evaluate the content validity and usability of the Raynaud Diary, a new electronic patient-reported outcome (PRO) measure for RP. Participants reported frequent RP symptoms such as color change, numbness, tingling, pain, and discomfort. Common triggers for RP attacks included temperature-related factors and stress. The participants demonstrated understanding of the Raynaud Diary instructions and indicated that they could use it to record the worst severity of individual RP symptoms.

ACR OPEN RHEUMATOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M. Forde, Jonathan Spicer, Nicolas Girard, Daphne Wang, Robert A. Anders, Edward Gabrielson, Peter Illei, Jaroslaw Jedrych, Ludmila Danilova, Joel Sunshine, Keith M. Kerr, Mia Tran, Judith Bushong, Junliang Cai, Vipul Devas, Jaclyn Neely, David Balli, Tricia R. Cottrell, Alex S. Baras, Janis M. Taube

Summary: Neoadjuvant immunotherapy plus chemotherapy improves event-free survival and pathologic response in resectable lung cancer. Pathologic response assessment after neoadjuvant therapy may serve as a survival surrogate.

NATURE MEDICINE (2023)

添加到收藏夹

Review Oncology

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Giannis Mountzios, Jordi Remon, Lizza E. L. Hendriks, Rosario Garcia-Campelo, Christian Rolfo, Paul Van Schil, Patrick M. Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean-Charles Soria, Solange Peters

Summary: Several trials are being conducted to test immune-checkpoint inhibitors (ICIs) in patients with resectable non-small-cell lung cancer as adjuvant, neoadjuvant or perioperative approaches. However, the efficacy of ICIs with curative intent in early stage non-small-cell lung cancer remains unclear. This review discusses the current trial landscape, challenges, and opportunities.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.